Strongbridge raises $53M in financing; Sienna Bio sets terms for $70M IPO
→ Strongbridge Biopharma has raised $53 million from CRG. Matthew Pauls, chief executive officer of Strongbridge, said: “We executed this financing to transform the financial outlook of the Company by fully funding our operating plan until we attain positive cash flow. The funds received at closing provide sufficient resources for us to build upon the early uptake and demand that we are seeing for Keveyis (dichlorphenamide), and to fund Recorlev (levoketoconazole) through potential regulatory approval and launch.”
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.